Each patient will be evaluated for up to 12, 16 or 20 weeks following a single intra-articular (IA) injection of FX006 at 10 mg or 40 mg or TCA IR 40 mg, depending on the assigned Cohort. Following the screening visit, safety will be evaluated at three (3) out-patient visits and synovial fluid will be collected at Day 1 for baseline measurements and the Final Visit for drug concentration measurements.